ProCUrE exhibited higher PPV than age-adjusted PSA for several different prognostic assessments (PPV: 76% vs 70.5% for CAPRA, 76% vs 72.1% for D’Amico, and 76% vs 63.9% for GS risk, Table 3B–D) indicating its overall robust ability to identify CS-PCa. The gene discussed is KLK3; the disease is posterior cortical atrophy.